

          -  Concurrent use of invasive mechanical ventilation (patients receiving non-invasive
             mechanical ventilation [CPAP, BiPap, HHFNC] are eligible)

          -  Concurrent use of vasopressor or inotropic medications

          -  Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor.

          -  Known history of hypersensitivity to tocilizumab.

          -  Patients who are actively being considered for a study of an antiviral agent that
             would potentially exclude concurrent enrollment on this study.

          -  Patients actively receiving an investigational antiviral agent in the context of a
             clinical research study.

          -  Diagnosis of end-stage liver disease or listed for liver transplant.

          -  Elevation of AST or ALT in excess of 5 times the upper limit of normal.

          -  Neutropenia (Absolute neutrophil count < 500/uL).

          -  Thrombocytopenia (Platelets < 50,000/uL).

          -  On active therapy with a biologic immunosuppressive agent.

          -  History of bone marrow transplantation or solid organ transplant.

          -  Known history of Hepatitis B or Hepatitis C.

          -  Known history of mycobacterium tuberculosis infection at risk for reactivation.

          -  Known history of gastrointestinal perforation or active diverticulitis.

          -  Multi-organ failure as determined by primary treating team

          -  Any other documented serious, active infection besides COVID-19.

          -  Pregnant patients

          -  Patients who are unable to discontinue scheduled antipyretic medications, either as
             monotherapy (e.g., acetaminophen or ibuprofen [aspirin is acceptable]) or as part of
             combination therapy (e.g., hydrocodone/acetaminophen, aspirin/acetaminophen/caffeine
             [Excedrin])

          -  CRP < 40 mg/L (or ug/mL)

        Patients will be assigned to Group A if:

         C-reactive protein (CRP) >= 75 ug/mL

        AND

        Any one of the following criteria are met:

          -  Previous ICU admission

          -  Previous non-elective intubation

          -  Admission for heart failure exacerbation within the past 12 months

          -  History of percutaneous coronary intervention (PCI)

          -  History of coronary artery bypass graft (CABG) surgery

          -  Diagnosis of pulmonary hypertension

          -  Baseline requirement for supplemental O2

          -  Diagnosis of interstitial lung disease (ILD)

          -  Admission for chronic obstructive pulmonary disease (COPD) exacerbation within the
             past 12 months

          -  Asthma with use of daily inhaled corticosteroid

          -  History of pneumonectomy or lobectomy

          -  History of radiation therapy to the lung

          -  History of HIV

          -  Cancer of any stage and receiving active treatment (excluding hormonal therapy)

          -  Any history of diagnosed immunodeficiency

          -  End-stage renal disease (ESRD) requiring peritoneal or hemodialysis

        All other eligible patients assigned to Group B
      